Haemonetics Co. (NYSE:HAE) Given Average Recommendation of "Moderate Buy" by Analysts

Haemonetics Co. (NYSE:HAE - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $101.67.

A number of equities research analysts have recently commented on the stock. JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. StockNews.com upgraded Haemonetics from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and reduced their target price for the stock from $95.00 to $68.00 in a report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock. Finally, Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th.

Haemonetics Stock Down 0.3 %

NYSE:HAE traded down $0.18 during trading hours on Friday, reaching $61.36. 1,107,316 shares of the company traded hands, compared to its average volume of 1,023,790. Haemonetics has a 1 year low of $58.80 and a 1 year high of $97.97. The stock has a market capitalization of $3.08 billion, a P/E ratio of 24.16, a P/E/G ratio of 0.98 and a beta of 0.39. The business's 50-day moving average price is $75.36 and its two-hundred day moving average price is $77.80. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts predict that Haemonetics will post 4.59 earnings per share for the current year.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Whittier Trust Co. purchased a new stake in shares of Haemonetics during the 4th quarter worth approximately $62,000. Nisa Investment Advisors LLC raised its stake in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 632 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares in the last quarter. Finally, KBC Group NV increased its holdings in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after buying an additional 712 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.